Cargando…

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer

LESSONS LEARNED: Concurrent ETBX‐011, ETBX‐051, and ETBX‐061 can be safely administered to patients with advanced cancer. All patients developed CD4(+) and/or CD8(+) T‐cell responses after vaccination to at least one tumor‐associated antigen (TAA) encoded by the vaccine; 5/6 patients (83%) developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatti‐Mays, Margaret E., Redman, Jason M., Donahue, Renee N., Palena, Claudia, Madan, Ravi A., Karzai, Fatima, Bilusic, Marijo, Sater, Houssein Abdul, Marté, Jennifer L., Cordes, Lisa M., McMahon, Sheri, Steinberg, Seth M., Orpia, Alanvin, Burmeister, Andrea, Schlom, Jeffrey, Gulley, James L., Strauss, Julius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288633/
https://www.ncbi.nlm.nih.gov/pubmed/31594913
http://dx.doi.org/10.1634/theoncologist.2019-0608
_version_ 1783545316424810496
author Gatti‐Mays, Margaret E.
Redman, Jason M.
Donahue, Renee N.
Palena, Claudia
Madan, Ravi A.
Karzai, Fatima
Bilusic, Marijo
Sater, Houssein Abdul
Marté, Jennifer L.
Cordes, Lisa M.
McMahon, Sheri
Steinberg, Seth M.
Orpia, Alanvin
Burmeister, Andrea
Schlom, Jeffrey
Gulley, James L.
Strauss, Julius
author_facet Gatti‐Mays, Margaret E.
Redman, Jason M.
Donahue, Renee N.
Palena, Claudia
Madan, Ravi A.
Karzai, Fatima
Bilusic, Marijo
Sater, Houssein Abdul
Marté, Jennifer L.
Cordes, Lisa M.
McMahon, Sheri
Steinberg, Seth M.
Orpia, Alanvin
Burmeister, Andrea
Schlom, Jeffrey
Gulley, James L.
Strauss, Julius
author_sort Gatti‐Mays, Margaret E.
collection PubMed
description LESSONS LEARNED: Concurrent ETBX‐011, ETBX‐051, and ETBX‐061 can be safely administered to patients with advanced cancer. All patients developed CD4(+) and/or CD8(+) T‐cell responses after vaccination to at least one tumor‐associated antigen (TAA) encoded by the vaccine; 5/6 patients (83%) developed MUC1‐specific T cells, 4/6 (67%) developed CEA‐specific T cells, and 3/6 (50%) developed brachyury‐specific T cells. The presence of adenovirus 5‐neutralizing antibodies did not prevent the generation of TAA‐specific T cells. BACKGROUND: A novel adenovirus‐based vaccine targeting three human tumor‐associated antigens—CEA, MUC1, and brachyury—has demonstrated antitumor cytolytic T‐cell responses in preclinical animal models of cancer. METHODS: This open‐label, phase I trial evaluated concurrent administration of three therapeutic vaccines (ETBX‐011 = CEA, ETBX‐061 = MUC1 and ETBX‐051 = brachyury). All three vaccines used the same modified adenovirus 5 (Ad5) vector backbone and were administered at a single dose level (DL) of 5 × 10(11) viral particles (VP) per vector. The vaccine regimen consisting of all three vaccines was given every 3 weeks for three doses then every 8 weeks for up to 1 year. Clinical and immune responses were evaluated. RESULTS: Ten patients enrolled on trial (DL1 = 6 with 4 in the DL1 expansion cohort). All treatment‐related adverse events were temporary, self‐limiting, grade 1/2 and included injection site reactions and flu‐like symptoms. Antigen‐specific T cells to MUC1, CEA, and/or brachyury were generated in all patients. There was no evidence of antigenic competition. The administration of the vaccine regimen produced stable disease as the best clinical response. CONCLUSION: Concurrent ETBX‐011, ETBX‐051, and ETBX‐061 can be safely administered to patients with advanced cancer. Further studies of the vaccine regimen in combination with other agents, including immune checkpoint blockade, are planned.
format Online
Article
Text
id pubmed-7288633
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-72886332020-06-12 A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer Gatti‐Mays, Margaret E. Redman, Jason M. Donahue, Renee N. Palena, Claudia Madan, Ravi A. Karzai, Fatima Bilusic, Marijo Sater, Houssein Abdul Marté, Jennifer L. Cordes, Lisa M. McMahon, Sheri Steinberg, Seth M. Orpia, Alanvin Burmeister, Andrea Schlom, Jeffrey Gulley, James L. Strauss, Julius Oncologist Clinical Trial Results LESSONS LEARNED: Concurrent ETBX‐011, ETBX‐051, and ETBX‐061 can be safely administered to patients with advanced cancer. All patients developed CD4(+) and/or CD8(+) T‐cell responses after vaccination to at least one tumor‐associated antigen (TAA) encoded by the vaccine; 5/6 patients (83%) developed MUC1‐specific T cells, 4/6 (67%) developed CEA‐specific T cells, and 3/6 (50%) developed brachyury‐specific T cells. The presence of adenovirus 5‐neutralizing antibodies did not prevent the generation of TAA‐specific T cells. BACKGROUND: A novel adenovirus‐based vaccine targeting three human tumor‐associated antigens—CEA, MUC1, and brachyury—has demonstrated antitumor cytolytic T‐cell responses in preclinical animal models of cancer. METHODS: This open‐label, phase I trial evaluated concurrent administration of three therapeutic vaccines (ETBX‐011 = CEA, ETBX‐061 = MUC1 and ETBX‐051 = brachyury). All three vaccines used the same modified adenovirus 5 (Ad5) vector backbone and were administered at a single dose level (DL) of 5 × 10(11) viral particles (VP) per vector. The vaccine regimen consisting of all three vaccines was given every 3 weeks for three doses then every 8 weeks for up to 1 year. Clinical and immune responses were evaluated. RESULTS: Ten patients enrolled on trial (DL1 = 6 with 4 in the DL1 expansion cohort). All treatment‐related adverse events were temporary, self‐limiting, grade 1/2 and included injection site reactions and flu‐like symptoms. Antigen‐specific T cells to MUC1, CEA, and/or brachyury were generated in all patients. There was no evidence of antigenic competition. The administration of the vaccine regimen produced stable disease as the best clinical response. CONCLUSION: Concurrent ETBX‐011, ETBX‐051, and ETBX‐061 can be safely administered to patients with advanced cancer. Further studies of the vaccine regimen in combination with other agents, including immune checkpoint blockade, are planned. John Wiley & Sons, Inc. 2019-10-08 2020-06 /pmc/articles/PMC7288633/ /pubmed/31594913 http://dx.doi.org/10.1634/theoncologist.2019-0608 Text en © AlphaMed Press; the data published online to support this summary are the property of the authors. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Clinical Trial Results
Gatti‐Mays, Margaret E.
Redman, Jason M.
Donahue, Renee N.
Palena, Claudia
Madan, Ravi A.
Karzai, Fatima
Bilusic, Marijo
Sater, Houssein Abdul
Marté, Jennifer L.
Cordes, Lisa M.
McMahon, Sheri
Steinberg, Seth M.
Orpia, Alanvin
Burmeister, Andrea
Schlom, Jeffrey
Gulley, James L.
Strauss, Julius
A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
title A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
title_full A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
title_fullStr A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
title_full_unstemmed A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
title_short A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
title_sort phase i trial using a multitargeted recombinant adenovirus 5 (cea/muc1/brachyury)‐based immunotherapy vaccine regimen in patients with advanced cancer
topic Clinical Trial Results
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288633/
https://www.ncbi.nlm.nih.gov/pubmed/31594913
http://dx.doi.org/10.1634/theoncologist.2019-0608
work_keys_str_mv AT gattimaysmargarete aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT redmanjasonm aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT donahuereneen aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT palenaclaudia aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT madanravia aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT karzaifatima aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT bilusicmarijo aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT saterhousseinabdul aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT martejenniferl aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT cordeslisam aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT mcmahonsheri aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT steinbergsethm aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT orpiaalanvin aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT burmeisterandrea aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT schlomjeffrey aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT gulleyjamesl aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT straussjulius aphaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT gattimaysmargarete phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT redmanjasonm phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT donahuereneen phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT palenaclaudia phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT madanravia phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT karzaifatima phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT bilusicmarijo phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT saterhousseinabdul phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT martejenniferl phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT cordeslisam phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT mcmahonsheri phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT steinbergsethm phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT orpiaalanvin phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT burmeisterandrea phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT schlomjeffrey phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT gulleyjamesl phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer
AT straussjulius phaseitrialusingamultitargetedrecombinantadenovirus5ceamuc1brachyurybasedimmunotherapyvaccineregimeninpatientswithadvancedcancer